Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 11/20 | 0.67 |
| ▸ | MAPT | P10636 | 11/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | GFER | P55789 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.63 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | SNCA | P37840 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 5/20 | 0.55 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.55 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063745 | 0.86 | GAA (0.70) | GAAMAPTL3MBTL1KDM4EALOX15 | |
| SCHEMBL4931553 | 0.84 | GAA (0.57) | GAAMAPTL3MBTL1KDM4EALOX15 | |
| SCHEMBL2475972 | 0.84 | GAA (0.63) | GAAMAPTL3MBTL1KDM4EALOX15 | |
| SCHEMBL14680275 | 0.81 | MAPT (0.78) | GAAMAPTL3MBTL1KDM4EALOX15 | |
| SCHEMBL2462363 | 0.81 | L3MBTL1 (1.00) | GAAMAPTL3MBTL1KDM4EALOX15 | |
| SCHEMBL10055033 | 0.80 | LMNA (0.61) | GAAMAPTL3MBTL1KDM4EALOX15 | |
| SCHEMBL6419238 | 0.80 | LMNA (0.61) | GAAMAPTL3MBTL1KDM4EALOX15 | |
| SCHEMBL13879814 | 0.80 | L3MBTL1 (0.63) | GAAMAPTL3MBTL1KDM4EALOX15 | |
| SCHEMBL1843773 | 0.80 | MAPT (0.80) | GAAMAPTL3MBTL1KDM4EALOX15 | |
| SCHEMBL19648939 | 0.79 | MAPT (0.59) | GAAMAPTKDM4EALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| WO-2011113060-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9173886-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TRANA DISCOVERY, INC (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011113060-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TYMP, MAVS, ZC3HAV1 | GAA 75/4885MAPT 3443/4885L3MBTL1 528/4885 |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | GAA 75/4885MAPT 3443/4885L3MBTL1 528/4885 |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TYMP, MAVS, ZC3HAV1 | GAA 75/4885MAPT 3443/4885L3MBTL1 528/4885 |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | GAA 75/4885MAPT 3443/4885L3MBTL1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.